Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Lupin Limited ( (IN:LUPIN) ).
Lupin Limited announced that its Bioresearch Center in Pune received zero observations from the U.S. FDA following a successful inspection and assessment. This outcome underscores Lupin’s commitment to quality and compliance, enhancing its reputation in the pharmaceutical industry and potentially strengthening its market position.
More about Lupin Limited
Lupin Limited is a global pharmaceutical leader based in Mumbai, India, with a presence in over 100 markets. The company specializes in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It holds a strong market position in India and the U.S. across various therapeutic areas such as respiratory, cardiovascular, anti-diabetic, and more. Lupin operates 15 manufacturing sites and 7 research centers worldwide, supported by over 24,000 professionals.
Average Trading Volume: 20,432
Technical Sentiment Signal: Buy
Current Market Cap: 893.4B INR
For detailed information about LUPIN stock, go to TipRanks’ Stock Analysis page.